Focus: ALX Oncology is an immuno-oncology biotech company focused on advancing early-stage cancer therapeutics targeting solid tumors and hematologic malignancies. The company operates from South San Francisco with a lean, focused pipeline in Phase 1/2 development.
Profile data last refreshed 11h ago · AI intelligence enriched 3w ago
Best for early-career scientists or clinical professionals seeking immuno-oncology depth and equity upside, but carry higher risk than mid-cap peers.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for ALX Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from ALX Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+2 more
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles